Back to results
US 2026/0083727 A1Published application
Pharmaceutical formulations of nintedanib for intraocular use
AssigneeBoehringer Ingelheim International GmbH
InventorsPaul ASHTON, Jianbing CHEN, Florian Andreas COLBATZKY, Hong GUO, Laibin LUO, Kerstin Julia SCHAEFER
Life of this patent
Estimating the term…
Abstract
Formulations and intravitreal implants containing nintedanib can be used in methods for the treatment of back-of-the-eye diseases.
Claims15
A long-term sustained-release pharmaceutical formulation of the API comprising 80 to 95% (w/w) of API and 5 to 20% (w/w) of poly polyvinyl alcohol (PVA).
Dependencies are inferred from the claim text.